RAS AL KHAIMAH, United Arab Emirates--(BUSINESS WIRE)--Julphar welcomed HE Gocha Buachidze, Consul General of the Russian Federation, accompanied by a delegation representing Russian healthcare companies. The visit aims to review Julphar’s extensive experience in MENA pharmaceutical industry and to discuss potential mutual cooperation.
The high-quality medicines manufactured by Julphar are recognized as strong brands with an international presence, as they are distributed to over 40 countries and provide effective treatment for a wide range of conditions, especially chronic diseases.
“The visit by HE the Consul General of the Russian Federation and his delegation, reflects our growing relations and the determination of both parties to reinforce cooperation in the healthcare sector,” said HH Sheikh Faisal Bin Saqr Al Qassimi, Chairman of the Board of Julphar.
“The visit of the Russian delegation was an opportunity to demonstrate Julphar’s numerous initiatives and efforts to enhance production facilities, state-of-the-art platforms for scientific research and technical development. With more than 200 products available in our portfolio, we believe we can contribute strongly to improve access to quality and affordable treatments for patients around the world, especially in the field of Diabetes Management,” said Jerome Carle, Julphar’s General Manager.
Sheikh Faisal bin Saqr Al Qassimi, Chairman of Julphar, briefed the visiting delegation about the company’s history, which started out as a standalone facility in 1980, and its ongoing commitment to implement the highest standards in pharmaceutical manufacturing. He also shed the light on the company’s pioneering initiatives that garnered local and international consumers’ confidence and its strong presence in Middle East and Africa.
The Consul General of the Russian Federation expressed his deep admiration for the significant achievements made by the company in the field of biotechnology with Insulin and Epotin. "Meeting with H.E Sheikh Faisal bin Saqr Al Qassimi has been an important opportunity to learn about Julphar, which is one of the most renowned and important drug manufacturer in the region, and to discuss ways to boost coordination, cooperation and promote mutual relations,” he said.
Following the reception, members of the delegation had the opportunity to visit Julphar XI, which is one of the most modern biotechnological plant in the region.
About Julphar
Established in 1980, Julphar is one of the largest pharmaceutical manufacturers in Middle East and North Africa, producing over 200 branded products across 16 facilities. Julphar’s mission is to offer high quality medicines at affordable prices. Our product portfolio includes Biotechnology, Wound and Women Care, Adult and Pediatric General Medicines, Gastro and Pain Management, Cardio-Metabolism, Diabetes Solutions and Consumer range. Julphar employs more than 3,000 people around the world and registered revenue of AED 1.45 billion in 2016. For more information, please visit our website http://www.julphar.net.
*Source: AETOS Wire
